Wart

Orphan designation: Mavorixafor Treatment of WHIM syndrome, 25/07/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, WHIM, WHIM syndrome, Myelokathexis, Pneumonia, Bone marrow, CXCR4, Risk, Patient, Committee, Knowledge, Hypogammaglobulinemia, Antibody, Regulation, Viral, EMA, IRIS, Wart, Otitis, Protein, Lymphocyte, European, Infection, COMP, Immune system, European Commission, Neutrophil, Blood, Safety, Consultant, Marketing, Movement, Pharmaceutical industry

Orphan designation: Mavorixafor Treatment of WHIM syndrome, 25/07/2019 Positive

Key Points: 


Orphan designation: Mavorixafor Treatment of WHIM syndrome, 25/07/2019 Positive

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Security (finance), WHIM, WHIM syndrome, Conference call, Conference, RPD, New Drug Application, Ageing, Orphan, Wart, NDA, Priority review, Research and development, Immune system, File, ID, FDA, X4, PDUFA, Pharmaceutical industry

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted key 2023 events and expected upcoming milestones.

Key Points: 
  • “Following an incredibly productive 2023, we are expecting a transformative year in 2024,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .
  • Following the completion of the call, a webcast replay of the conference call will be available on the company website.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, MD, FDA, Infection, Cryotherapy, Skin, Common, MBA, Finger, Viral, Safety, Nielsen, Wart, Patient, Clinical trial, HPV, FAAD, Trial of the century, Pharmaceutical industry

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.

Key Points: 
  • Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
  • Nielsen is partnering with Maruho Co. Ltd. (“Maruho”) in the clinical development program for CANDIN.
  • “The first patient treated with CANDIN represents a major milestone for the company, and for patients affected by common warts around the world,” said David P. Burney, PhD, MBA, President and Chief Operating Officer at Nielsen BioSciences.
  • Common warts are estimated to affect approximately 10 percent of the global population.1 There are currently no FDA-approved prescription treatments.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Golden State Dermatology Announces New Torrance Partnership

Retrieved on: 
Wednesday, February 21, 2024
Rash, Psoriasis, Greater Los Angeles, Acne, Dermatology, Golden, Pediatrics, Filler (linguistics), Wart, Torrance Memorial Medical Center, Health, Patient, Lip, Dermatitis, Diagnosis, GSD, Laser, Insurance, Partnership

TORRANCE, Calif., Feb. 21, 2024 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Shirlene Jay, MD, and her team in Torrance. This new practice expands the GSD Network as the fourth location in the Greater Los Angeles Area.

Key Points: 
  • TORRANCE, Calif., Feb. 21, 2024 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Shirlene Jay, MD, and her team in Torrance.
  • As a member of Golden State Dermatology, I look forward to streamlining administrative duties and channeling my focus and energies even more towards the patient care I enjoy so much," said Shirlene Jay, MD.
  • To learn more about Golden State Dermatology and their new partnership with Shirlene Jay, MD, please visit GoldenStateDermatology.com .
  • The founder of Golden State Dermatology, Edward Becker, MD said, "We're proud to support our clinicians to provide the highest-quality patient-centered care possible.

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Senior, Letter, Joint venture, Investment, Marketing, FDA, Hemorrhoid, Note, Herpes labialis, Wart, JV, BMI, License, Patient, Pruritus ani, Anal, Body mass index, Failure, Glycated hemoglobin, Partnership, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

Certified Foot and Ankle Specialists Take Action to Support Children Affected by Medicaid Cuts in Florida

Retrieved on: 
Monday, January 22, 2024
Sentinel, Medicaid, Orlando Sentinel, Fracture, DPM, Ankle, Insurance, Sprain, Foot, Sentinel (comics), Child, Wart, Three-body problem, Wound

BOCA RATON, Fla., Jan. 22, 2024 /PRNewswire-PRWeb/ -- In response to alarming reports by the Orlando Sentinel, which state that over 800,000 Florida residents were removed from the state's Medicaid program between March and September, Certified Foot and Ankle Specialists has embarked on a charitable mission to address the healthcare needs of children adversely affected by these changes.

Key Points: 
  • "We are committed to providing free medical care to children who have lost Medicaid coverage in Florida, due to avoidable circumstances and administrative hurdles."
  • - Dr. Kyle Kinmon DPM (Founder, Certified Foot and Ankle Specialists)
    It has been reported that approximately 360,000 children have been severely impacted by these Medicaid removals, with many losing access to vital healthcare services.
  • "At Certified Foot and Ankle Specialists, we firmly believe that every child in Florida should have access to comprehensive healthcare, regardless of insurance coverage.
  • " - Dr. Kyle Kinmon, DPM (Founder, Certified Foot and Ankle Specialists)

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

Retrieved on: 
Thursday, January 4, 2024
FDA, Type, Food, Dermatology, Therapy, Skin, Wart, Pharmaceutical industry

More specifically, the Company believes that the Type C meeting satisfied its objective to gain the FDA’s advice and agreement on the overall design of a pivotal Phase 3 study of YCANTH that would support an efficacy supplement for the proposed indication of common warts.

Key Points: 
  • More specifically, the Company believes that the Type C meeting satisfied its objective to gain the FDA’s advice and agreement on the overall design of a pivotal Phase 3 study of YCANTH that would support an efficacy supplement for the proposed indication of common warts.
  • YCANTH is currently only approved to treat molluscum contagiosum in adults and children two years of age and older.
  • “We believe our recent Type C meeting with the FDA was highly productive and led to mutual alignment with respect to the design of a Phase 3 development plan to evaluate YCANTH for the treatment of common warts,” said Ted White, President & Chief Executive Officer of Verrica Pharmaceuticals.
  • We remain focused on addressing some of the largest unmet needs in dermatology, and the successful outcome of this Type C meeting is an important step forward as we evaluate label expansion opportunities for YCANTH.”